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ABSTRACT _
Our current understanding of some mechanisms involved
with the occurrence of acute coronary events indicates
that coronary atherosclerotic plaques need not develop
to the point of stenosis before resulting in an acute
event. Recent studies show that the majority of myocar-
dial infarctions result from lesions that are 30-60%
stenotic, many of which are not associated with any
overt clinical symptoms. Considering that every year in
Introduction
Coronary disease is still the largest killer of men
and women in the United States. About one and a
half million myocardial infarctions (MIs) occur
every year in the US. From this group, approxi-
mately one quarter of a million persons die sud-
denly from their MIs; many of whom did not have
or were not aware that they had pre-existing coro-
nary disease. By age 60, approximately every 5th
man and every 17th woman have developed coro-
nary disease. The cost to society associated with
coronary disease is significant.
Even though the numbers remain high, there
have been decreases in age-adjusted coronary mor-
tality rates over the last several decades. Attempts
have been made to explain these kinds of de-
creases. An article recently published in JAMA [1]
analyzed the decline in coronary mortality between
1980 and 1990 by examining the factors that
could explain this decrease. It was concluded that:
1) 43 % of the reduction in age-adjusted coronary
mortality was due to acute treatment and revascu-
larization of patients who presented with ischemic
syndromes or with coronary disease; 2) another
29% was due to reduction of risk factors in pa-
tients with coronary disease; and 3) only 25% was
actually due to risk-factor reduction with primary
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the United States, = 200,000 persons with no previous
history of coronary disease die from their first myocar-
dial infarction, a major issue becomes identifying persons
at risk for coronary disease. Risk assessment for coro-
nary events is a critical area in terms of moving forward
with decision-making for lipid-lowering therapies and
developing strategies to reduce acute coronary events,
and the morbidity and mortality related to them.
prevention in patients without pre-existing disease.
Progress is being made, but we still have a long way
to go in terms of more sophisticated identification
of people at risk, and employment of proven strate-
gies in the primary prevention setting.
Current Understanding of Acute Coronary
Event Genesis
Angiographic-regression trials completed over the
last few years have caused a shift in our under-
standing of how acute coronary events occur. His-
torically, our conception has been based on the
paradigm that plaque formation and coronary dis-
ease progressed over years and decades to the point
where vessels became flow-limiting and stenotic;
finally, a portion of the plaque plugged off with
some platelets and caused an acute coronary event.
Over the last few decades, several trials have tested
the hypothesis that if you take patients with es-
tablished coronary disease, angiographically docu-
mented, treat them to lower their cholesterol, and
then repeat an angiogram 2 to 4 years later, the lu-
minal diameter of the vessel will improve. These
studies have taught us a great deal, and a selection
of them is summarized in Table 1 [2,3]. Most have
shown a difference between the treated group and
the control group in terms of luminal diameter,
minimum luminal diameter, or other read-outs from
the angiography (Table 1, angiographic results).
However, the magnitude of these differences has
been quite small, on the order of fractions of milli-
meters difference between the two groups. Results
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Table I Angiographic and coronary event outcomes in lipid intervention models
Rader
Duration
Angiographic results!
Coronary events!
Study Therapy (years) Control Treated (% event reduction)
NHLBIType II Diet + resin 5 33
CLAS Diet + resin + niacin 2 +2.65 +0.35 25
POSCH Diet + surgery ± resin 9.7 35*
Lifestyle Heart Study Vegetarian diet + relaxation + exercise I 3.4 -2.2*
FATS Diet + resin + niacin 2.5 +2.1 '-0.9* 80*
FATS Diet + resin + lovastatin 2.5 -'-2.1 -0.7* 70
CLAS II Diet + resin + niacin 4 43
UCSF·SCOR Diet + resin + niacin ::': lovastatln 2 +0.8 -1.5
STARS Diet 3 +5.8 1.1 69*
STARS Diet + resin 3 +5.8 -1.9 89*
SCRIP Diet + drugs + exercise 4 +0.9 +0.3* 50*
MARS Diet + lovastatin 2 +2.22 + 1.6 24
PLAC-I Diet + pravastatin 3 +1.11 to.67 62*
PLAC-2 Diet + pravastatin 3 60
CCAIT Diet + lovastatin 2 +2.89 +1.66* 25
*Achieved statistical significance.
!% change from angiographic baseline.
'Treated group vs control group.
NHLBI.National Heart, Lung and Blood Institute LipidStandardization Program; CLAS,The Cholesterol Lowering Atherosclerosis Study; POSCH, Program on the
SurgicalControl of Hypercholesterolemia; FATS,Familial Atherosclerosis Treatment Study; UCSF-SCOR, University of California. San Francisco Specialized Center
of Research in Atheriosclerosis Trial; STARS. St. Thomas' Atherosclerosis Regression Study; SCRIP, Stanford Coronary Risk Intervention Project; MARS. Moni-
tored Atherosclerosis Regression Study; PLAC. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries; CCAIT. Canadian Coronary Atherosclerosis
Intervention Trial.
Adapted from [2,3].
were statistically significant in some cases, but the
clinical significance of these changes was not es-
tablished until about 4 years ago when these trials
began reporting clinical event reductions in the
treated groups versus the control groups (Table 1,
coronary events). These trials, most of which were
short (2 to 4 years), showed remarkable reduc-
tions in clinical events. It is acknowledged that
they were not powered to address this question
and the patient numbers were small; nevertheless,
in aggregate, the results suggest that something is
occurring with these therapies that cannot be ex-
plained simply by anatomical changes in luminal
diameter. Perhaps clinical events should be the
real gold standard to focus on for clinical deci-
sion-making.
Angiographic regression studies provided fur-
ther information. One of the earliest was the Fa-
milial Atherosclerosis Treatment Study (FATS) r21.
Brown's group went back and determined, for
those patients who had acute events during the
course of the trial, what the diameters were of the
lesions prior to the events. The original angiograms
provided baseline measures, and the nature of those
lesions was analyzed. It was found that only two of
the acute coronary syndromes that patients pre-
sented with in this trial were the result of disrup-
tions of lesions that were greater than 70% stenotic
at the time of the initial angiogram. The majority of
clinical events that occurred were the result of le-
sions between 30% and 60% stenotic, suggesting
that our classic concept of very tight lesions causing
most coronary events was not correct.
A review by Falk r31 summarized four trials over
the last decade that were similar in design. From
these trials, patients were studied who underwent
angiography for coronary disease symptoms or be-
cause of positive stress-tests and subsequently had
acute MIs. Post MI, another angiogram was taken;
hence, the extent of the lesion that caused the MI
could be identified. From initial angiograms in
these four trials, the percentage stenosis indicated
that 68% of all acute MIs in these trials were the
result of lesions that were less than 50% stenotic
on the initial angiogram, another 18 % were asso-
ciated with 50-70% stenotic lesions, and only
14%, were due to lesions greater than 70%. Again,
our concept of tight lesions as the common cause
of MIs is challenged.
A New Paradigm for Acute Coronary
Event Genesis
The studies described above suggest that many
acute coronary events are caused by lesions not
considered very important using traditional angio-
graphic measures. Atherosclerotic plaque can de-
velop and maintain a relatively normal lumen be-
cause of compensatory dilatation of the vessel at
the site of atherosclerotic plaque development. We
know now that a normal angiogram does not
mean with certainty that coronary plaque is not
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already present. A plaque can progress to a 30-
50% lesion that is not flow-limiting. This type of
lesion would not be expected to cause symptoms,
would not be expected to result in a positive
stress-test, and would not be expected to generate
collaterals because it is not flow-limiting. Never-
theless, many of these lesions are unstable or vul-
nerable; they have active inflammation and poor
fibrous caps. An acute event exposes the plaque
contents to blood space and generates a thrombus
that, under the right circumstances, can cause an
acute coronary event.
This new paradigm for acute coronary event
onset alters our way of our thinking about preven-
tion. A significant issue is how to determine those
who have these lesions or are statistically likely to
develop them, and to employ therapies to prevent
progression to an acute coronary event. The stan-
dard clinical approach was based on the classic
paradigm where subcritical or noncritical coro-
nary plaques progressed over years and decades to
stenotic lesions that caused patients to present
with symptoms. These patients were then candi-
dates for revascularization based on those symp-
toms. The new school of thought indicates another
pathophysiology wherein disruption of a non-flow-
limiting plaque results in an acute coronary event.
Our challenge is to identify this population to bet-
ter use therapies proven to stabilize unstable
plaques and reduce risk. Only through continued
investigation in animals and humans will the mech-
anisms of disease process and treatment be discov-
ered, and only then will a better understanding of
unstable plaques and how to predict and diagnose
them result.
Current Views of Decision-Making for
Lipid-Lowering Treatment
The contribution of cholesterol, specifically low
density lipoprotein (LDL), to the generation, initi-
ation, and propagation of atherosclerotic plaques
is still not well understood. LDL gets into vessel
walls, appears to become oxidized, is taken up by
macrophages, and generates an inflammatory re-
action. We are not sure how reducing blood cho-
lesterol impacts this process, but lowering lipids
has been proven to reduce acute coronary events.
The medical community agrees that lipid-lower-
ing therapy is an accepted method of secondary
prevention and will treat aggressively those people
with established coronary disease. Others, poten-
tially at high risk with many risk factors for devel-
oping disease but having no overt symptoms, are
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candidates for primary prevention. Some will argue
that resources should be focused on people who al-
ready have disease (secondary prevention) and not
be used for primary prevention. However, with re-
cent evidence showing that most acute MIs occur
because of rupture of non-flow-limiting lesions, the
importance of primary prevention increases. About
half of all MIs occur in people without primary cor-
onary disease, and somewhere between a quarter
and a third of all first MIs are fatal-a statistic with
tremendous implications for the importance of
early identification of risk. Every year in the US,
about 200,000 people with no previous history of
coronary disease die suddenly of their first MI; this
group never has the opportunity for secondary pre-
vention. We should be able to prevent some of
these deaths.
Three major issues faced in the field of lipid-low-
ering are 1) deciding who should be treated; 2) de-
veloping better decision-making algorithms; and 3)
identifying those at highest risk. To provide a
clearer framework to address these issues, we must
think more quantitatively about risk; for example,
risk-imminent events over a 5-year period can be
estimated. People with established coronary disease
have a high risk (25-30%) over 5 years of having
another coronary event. The medical community
treats patients with coronary disease very aggres-
sively. With an average risk for 50-year-old men of
about 5% per 5 years, why not identify high-risk
subgroups of people who are at risk in the 10-20%
range and focus resources aggressively on primary
prevention for this group?
Risk Assessment: Present and Future
High-risk people are currently identified by tradi-
tional risk factors. Risk increases with the presence
of increasing numbers of these risk factors. The use
of multivariate risk models to analyze a variety of
clinical data can provide 5-year risk assessments for
individuals. Some patients will be found to be obvi-
ously at risk. Patient A in Table 2, even in the ab-
sence of very high LDL levels, is clearly a candidate
for intervention based on the presence of several
other risk factors. It is more difficult to assess pa-
tients seen in practice who are not obvious, clear-
cut cases, like patient B in Table 2, who has a fam-
ily history of coronary disease, LDL levels just over
the 160 threshold, and no other risk factors.
For this type of patient, better risk assessment
techniques are needed to optimize treatment deci-
sions. Laboratory testing could be included to fur-
ther refine our ability to assess risk. In addition to
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Table 2 Making the decision to use lipid-lowering agents:
patient profiles
might be used to determine the presence of plaque
and identify higher risk subgroups.
Patient A Patient B
HDL, high density lipoprotein; LDL, low density lipoprotein,
Cholesterol Levels and Coronary Disease
Many who develop coronary disease do not have
particularly elevated cholesterol levels. In secondary
prevention, when coronary disease is present, even if
cholesterol levels are in the average range, drug ther-
apy is still warranted. The challenge for the future is
moving into primary prevention where people who
are clearly identified as high risk for developing fu-
ture coronary disease, despite cholesterol levels in
the average range, might be considered for preven-
tive treatment with cholesterol-lowering drugs.
Gray zone
48-year·old male
Healthy, active
None
Absent
Positive
Normal weight
168
237
164
39
Aggressive
46-year-old male
Sedentary
Type II
Present
Positive
Slightlyoverweight
210
238
167
29
Age. sex
lifestyle
Diabetes
Hypertension
Familyhistory
Weight
Triglycerides (mg/dL)
Cholesterol (mg/dL)
LDL (mgldL)
HDL (mgfdL)
Treatment decision
based on profile
,--------------
using a laboratory test that measures high or low
density lipoprotein (HDL or LDL) to assist in mak-
ing decisions about treatment, are there other tests
that could be added to our treatment decision algo-
rithms? Perhaps we should measure apoli (the ma-
jor protein in LDL), small dense LDLs, or the LDL
patterns that appear to be independent risk factors
for coronary disease. Lipoprotein(a} [Lp(a}], homo-
cysteine, and other indicators with some clinical and
epidemiologic data supporting them have also been
proposed as possible tests. With added information
from other laboratory tests, decisions to treat (or
not treat) "gray zone" patients may become dearer.
Looking again at patient B in Table 2, if this patient
had some additional test results showing elevated
apoB, elevated Lp(a), and/or elevated homocysteine,
the threshold for treatment might go down. With a
higher risk indication than that based on clinical
presentation alone, a decision could be made to
treat with lipid-lowering agents.
One other category in which there is intense in-
terest is that of noninvasive vascular imaging,
where people with established plaque can be iden-
tified noninvasively, thereby selecting a higher risk
subgroup for more aggressive intervention. Ca-
rotid ultrasound and electron beam computerized
tomography (ultrafast CT) are modalities that
Conclusions
A major paradigm shift has occurred with respect
to our thinking about the onset of coronary events.
It now seems that such events are due mostly to dis-
ruption or rupture of unstable, non-flow-limiting
coronary lesions, and not to the stenotic, flow-lim-
iting lesions that were previously thought to be re-
sponsible. Our current challenges lie in identifying
people who have these lesions or are at risk for de-
veloping them, and using proven therapies such as
lipid lowering in primary prevention to reduce the
likelihood of coronary events.
This article was prepared with the assistance of BioMed-
Com Consultants inc.,Montreal, Canada.
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